xMedica

NCT06531824ClinicalTrials.gov

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting…

Fase 311.000 partecipanti ricercati557 centri20 paesi

Categorie

Nefrologia e urologia53%Cardiovascolare41%Endocrino e metabolico4%Ostetricia e ginecologia2%

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Registered before enrolment beganFirst posted 2024-08-01; recorded start 2024-08-30
  • Has a defined primary outcomeA primary outcome measure is listed in the record
  • The primary outcome states a time frameThe primary outcome measure records a time frame
  • Participants are randomly assignedAllocation is recorded as randomised
  • Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Uses blinding (masking)A masking level is recorded in the record
  • An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Sponsor has 1218 other studies in this databaseCounted from the lead sponsor named in the record (Boehringer Ingelheim)
  • Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type10/10

    Mortality / MACE endpoint (hard clinical outcome)

  • Multi-centre8/8

    Multi-centre: 480 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEGA

A very large study, international in scope: 11,000 participants (target), run at 557 sites, across 20 countries.

How this score is built
  • Enrolment38/40

    11,000 participants (target)

  • Site count25/25

    480 sites

  • Country count15/15

    20 countries

  • Planned duration9/10

    Planned over about 49 months

  • Sponsor scale10/10

    Boehringer Ingelheim has led 1,211 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

This study is open to adults with chronic kidney disease at risk of progression. People with and without type 2 diabetes can take part in this study. The study is open to people who take other medicines called angiotensin converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). People who already take empagliflozin or any other sodium-glucose cotransporter-2 inhibitor (SGLT2i) can also join. The study is also open to people who currently do not take any of these treatments. The purpose of this study is to find out whether a medicine called BI 690517 helps people with chronic kidney disease when taken in combination with a study medicine called empagliflozin. Worsening of kidney function increases the risk for kidney failure, cardiovascular disease, and heart failure hospitalisation. After a run-in period, during which participants are confirmed to be receiving clinically appropriate renin-angiotensin system blockade and are established on empagliflozin, they are randomly assigned (by chance) to 1 of 2 groups. One group receives BI 690517 tablets, and the other group receives placebo tablets. Placebo tablets look like BI 690517 but do not contain any medicine. Participants take 1 study tablet once a day, in addition to empagliflozin, for the duration of the study. The doctors document when participants experience worsening of their kidney disease, go to hospital due to heart failure, or die of cardiovascular problems during the study. The time to these events is compared between the 2 treatment groups to see whether the treatment works. The study continues until the required number of events have occurred which is about 3 to 4 years. During this time, participants visit the study site about 5 times within the first 6 months. Then they visit the study site every 6 months. At the visits, doctors regularly check participants' health, take blood and urine samples, measure blood pressure and weight, check kidney function, and take note of any unwanted effects.

Patologie

  • Kidney Disease, Chronic

Idoneità

SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Key Inclusion Criteria: * Evidence of chronic kidney disease (CKD) at risk of kidney disease progression is defined on the basis of local laboratory results recorded at least 3 months before and at the time of the Screening visit, and requires: 1. Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR ≥20 \<45 mL/min/1.73m² (irrespective of diabetes status); or 2. No self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with urine albumin-to-creatinine ratio (uACR) ≥150 mg/g (or protein-to-creatinine ratio ≥225 mg/g); or 3. Self-reported diabetes: CKD-EPI eGFR ≥45 \<90 mL/min/1.73m² with uACR ≥30 mg/g (or protein-to-creatinine ratio ≥45 mg/g). * Neither requires an Aldosterone Synthase inhibitor (ASi) or Mineralocorticoid Receptor Antagonist (MRA), nor that such treatment is definitely inappropriate. Key Exclusion Criteria: * Blood potassium of \>5.2 mmol/L at screening visit * Blood Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \>3x Upper Limit of Normal (ULN) at Screening visit (only one is required, with ALT preferred) * Known liver cirrhosis * On dialysis, functioning kidney transplant, or scheduled living donor transplant * Treated with new immunosuppression therapy for new (or relapse/flare of pre-existing) kidney disease within the last 60 days * Receiving more than one Renin-Angiotensin System (RAS) inhibitor (i.e. on dual therapy with two of an Angiotensin-Converting Enzyme inhibitor (ACEi), Angiotensin Receptor Blocker (ARB) or direct renin inhibitor) * Currently treated with an Mineralocorticoid Receptor Antagonist (MRA) (e.g. spironolactone, eplerenone, finerenone) * Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Tipo di studioInterventistico
FaseFase 3
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoQUADRUPLE (4)
Arruolamento11.000 partecipanti ricercati

Sponsor e collaboratori

  • Boehringer Ingelheim Sponsor

Bracci e interventi

  • Part 1: Run-in period (all participants)OTHER

    * Participant will receive empagliflozin (called Type E) together with study tablets (called Type F) prior to later randomisation to the main study treatment (Type M). * This run-in period allows empagliflozin to be established and have its effects on kidney function before randomisation, and to make sure participant can tolerate empagliflozin long-term. Participants will not routinely know whether type F treatment is active or inactive so that participants can become familiar with taking main study tablet (Type M) after randomization.

  • Part 2: Randomized treatment, follow-up period, treatment groupEXPERIMENTAL
  • Part 2: Follow-up period, placebo groupPLACEBO_COMPARATOR

Interventi

  • Farmaco BI 690517

    BI 690517 (called Type M randomized treatment)

  • Farmaco Empagliflozin

    Empagliflozin (called Type E)

  • Farmaco Placebo matching BI 690517

    Placebo matching BI 690517

Esiti misurati

  1. Esito primario

    Time to first occurrence of the primary composite outcome of: (i) Kidney disease progression*; or (ii) Hospitalization for heart failure; or (iii) Cardiovascular death.

    Kidney disease progression is defined as kidney failure or a sustained decline of ≥40% in estimated Glomerular Filtration Rate (eGFR) from randomization

    Orizzonte temporale up to 4 years

  2. Esito secondario

    Key secondary outcome: Time to first event of kidney failure, hospitalization for heart failure or cardiovascular death

    Orizzonte temporale up to 4 years

  3. Esito secondario

    Key secondary outcome: Time to first event of hospitalization for heart failure or cardiovascular death

    Orizzonte temporale up to 4 years

  4. Esito secondario

    Key secondary outcome: Occurrences of hospitalizations from any cause (first and any subsequent, combined) or death from any cause

    Orizzonte temporale up to 4 years

  5. Esito secondario

    Key secondary outcome: Time to death from any cause

    Orizzonte temporale up to 4 years

  6. Esito secondario

    Key secondary outcome: Annual rate of change in eGFR from 1 month until last scheduled visit (i.e. chronic eGFR slope)

    Orizzonte temporale up to 4 years

  7. Esito secondario

    Time to first event of kidney disease progression or cardiovascular death

    Orizzonte temporale up to 4 years

Date

Data di inizio30 agosto 2024 (effettiva)
Conclusione primaria30 agosto 2028 (stimata)
Conclusione30 agosto 2028 (stimata)
Prima pubblicazione1 agosto 2024 (effettiva)
Ultimo aggiornamento17 settembre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltasettembre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

557 centri stanno reclutando

Argentina

StrutturaCittàStato o regioneStato
Fundacion INTECNUSBarilocheIn reclutamento
Terapia Renal DomiciliariaBuenos AiresIn reclutamento
Centro de Salud Renal Junin SRLBuenos AiresIn reclutamento
Dres. Iribarren & Asoc. ConsultarioBuenos AiresIn reclutamento
Glenny Corp - Centro Medico SaavedraBuenos AiresIn reclutamento
CPSIC SRL - Cardiologia PalermoCABAIn reclutamento
Sanatorio Pasteur S.ACatamarcaIn reclutamento
CEMICCiudad Autonoma Buenos AiresIn reclutamento
CIMEL Chahin - Chahin S.A.Lanús EsteIn reclutamento
Centro Nefrologico del MarMar del PlataIn reclutamento
Mains BleuesRafaelaIn reclutamento
Sanatorio Parque S.A.RosarioIn reclutamento
Hospital Privado de RosarioRosarioIn reclutamento
Instituto de Nefrourologia y Nutricion de SaltaSaltaIn reclutamento
Clinica El CastañoSan JuanIn reclutamento
Centro de Investigaciones Medicas TucumanSan Miguel de TucumánIn reclutamento
Centro Integral de Medicina Respiratoria - CIMERSan Miguel de TucumánIn reclutamento
Instituto de Investigaciones Clinicas de RosarioSanta FeIn reclutamento
CEREHA S.A.- Centro de Estudios Renales e Hipertension ArterialVilla DomínicoIn reclutamento

Australia

StrutturaCittàStato o regioneStato
Flinders Medical CentreBedford ParkSouth AustraliaIn reclutamento
Eastern Health-Box Hill HospitalBox HillVictoriaIn reclutamento
Renal Research, GosfordGosfordNew South WalesIn reclutamento
Austin HealthHeidelberg HeightsVictoriaIn reclutamento
St George HospitalKogarahNew South WalesIn reclutamento
Liverpool HospitalLiverpoolNew South WalesIn reclutamento
The Alfred HospitalMelbourneVictoriaIn reclutamento
St Vincent's Hospital MelbourneMelbourneVictoriaIn reclutamento
Macquarie UniversityNew South WalesIn reclutamento
Westmead HospitalNew South WalesIn reclutamento
Hervey Bay HospitalPialbaQueenslandIn reclutamento
Port Macquarie Base Hospital (PMBH)Port MacquarieNew South WalesIn reclutamento
Griffith UniversitySouthportQueenslandIn reclutamento
Sunshine HospitalSt AlbansVictoriaIn reclutamento
Toowoomba HospitalToowoombaQueenslandIn reclutamento

Belgium

StrutturaCittàStato o regioneStato
AZ Sint-Jan BruggeBrugesIn reclutamento
Ziekenhuis Oost-LimburgGenkIn reclutamento
UZ BrusselJetteIn reclutamento
Centre Hospitalier Universitaire de LiègeLiègeIn reclutamento

Brazil

StrutturaCittàStato o regioneStato
Centro de Pesquisa Clínica do CoraçãoAracajuIn reclutamento
Santa Casa de Belo HorizonteBelo HorizonteIn reclutamento
Centro de Pesquisa do Hospital Evangelico de Belo HorizonteBelo HorizonteIn reclutamento
Universidade Estadual Paulista "Julio De Mesquita Filho"BotucatuIn reclutamento
Hospital Universitário São Francisco na Providência de DeusBragança PaulistaIn reclutamento
CEG - Centro de Endocrinologia GelonezeCampinasIn reclutamento
Instituto Cardiovascular de Linhares LtdaCentro LinharesIn reclutamento
PUC Trials - Núcleo de Pesquisa Clínica da Escola de Medicina da PUC-PRCuritibaIn reclutamento
Hospital Universitário Walter Cantídio - UFCFortalezaIn reclutamento
Centro de Pesquisas em Diabetes e Doencas MetabolicasFortalezaIn reclutamento
Hospital Ruy AzeredoGoiâniaIn reclutamento
Clínica CENDI Endocrinologia e DiabetesGoiâniaIn reclutamento

Nella scheda del registro sono indicati altri 507 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 17 settembre 2026

    Centro aggiunto

    37 sites added (557 total)

    520557

  2. 2 settembre 2026

    Centro aggiunto

    5 sites added (520 total)

    515520

  3. 21 agosto 2026

    Centro aggiunto

    18 sites added (515 total)

    497515

  4. 10 agosto 2026

    Centro aggiunto

    17 sites added (497 total)

    480497

Registro: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT06531824